Diagnosing Alzheimer's disease and schizophrenia
US5429947A · kind A · utility
3Cited by
3References
5Claims
0Family size
Inventors
Key dates
| Filing date | Jun 17, 1992 |
| Grant date | Jul 4, 1995 |
| Priority date | — |
| Expiry date | Jun 17, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/811
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for detecting elevated levels of the middle isoform of .alpha.-2 haptoglobin, .alpha.-2FS haptoglobin in bodily fluids of subjects with Alzheimer's disease and schizophrenia as compared with the .alpha.-2FS haptoglobin level in normal subjects. Fibrinogen fragments corresponding to proteins 127 and 128 are also found in elevated levels in such subjects. Elevated levels of specific haptoglobin proteins serve as a diagnostic marker for Alzheimer's disease and Schizophrenia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.